Terumo

Rank: 28
2015 Rank20
Employees19,934
Revenue:$4,043,833,127
R&D Spend:$286,981,780
Fiscal year ending:03-31-15
Click here to see all 100

Two years after Terumo scratched a distribution deal with Boston Scientific for its GlideWire urology device to go it alone, it turned to Olympus to distribute the device (having failed in its bid to merge with Olympus in the wake of that company's $17 billion accounting scandal in 2012). The company also inked a deal for a bioresorbable drug-eluting coronary stent made by France-based Arterial Remodeling Technologies, a deal that includes an exclusive buyout option. Another deal with Arterial Remodeling calls for the Japanese company to make a series of RandD investments in coronary stent technology. Terumo also launched the Misago RX self-expanding peripheral stent in the U.S., for patients with peripheral artery disease in the superficial femoral artery or proximal popliteal artery.

TERUMO® Launches Expanded Glideway™ Access Sheath Portfolio With A New Product For Minimally Invasive Urologic Procedures

2015 Top 500 Solar Contractors Key Personnel: Yutaro Shintaku, President & CEO; Hiroshi Matsumura, EVP, PR; Takayoshi Mimura, SVP; Shinjiro Sato, EVP, President, Cardiac & Vascular; Toshiaki Takagi, EVP & CQO; Shoji Hatano, EVP, President, General Hospital; Hideo Arase, EVP; Kuniko Shoji, EVP & Chief Clinical and Regulatory Affairs Officer; David Perez, EVP.;

2-44-1 Hatagaya
Shibuya-ku, Tokyo
151-0072
Japan